Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Gears Up For New Cholesterol Therapies, Winds Down Diagnostics

Executive Summary

Building on two strategic initiatives announced last year - the acquisition of Kos and a collaboration with AstraZeneca - Abbott is gearing up to expand its commercial presence and late-stage pipeline in the cholesterol treatment market this year, President and Chief Operating Officer Richard Gonzalez said during the company's year-end sales and earnings call Jan. 24

You may also be interested in...



Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009

Abbott plans to submit a fixed-dose statin-fenofibrate combination with AstraZeneca's Crestor in 2009, the company reported during a June 18 sales and earnings call

Schering Tries To Lower Merck HDL Agent Expectations, Without Razing JV

Schering-Plough is downplaying the potential impact of Merck's investigational niacin products on its cholesterol agents Zetia and Vytorin, which the firm markets through a joint venture with Merck

Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition

Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel